Verona Pharma announced Dr Sven Jan-Anders Karlsson as its new chief executive officer after last week’s news that AstraZeneca chief executive David Brennan resigned.
As a director serving on AstraZeneca’s board, Dr Karlsson is also executive vice-president of Pharma Global Research at Bayer Healthcare.
Dr Karlsson has broad pharmaceutical and biotechnology R&D and corporate experience. Formerly Karlsson was CEO at S*BIO, a Singapore and US based biotechnology company focused on the discovery and development of unique and new molecular anti-cancer drugs.
Commenting on the move, specialist in the discovery of treatments for chronic respiratory diseases such as asthma. Verona Pharma said it was extremely pleased with the addition of Dr Karlsson as its new executive vice-president.
A spokesperson for Verona said: “We are positive that the contributions Dr Karlsson will make to Verona Pharma will be significant, and senior-level staff are looking forward to working with him.